Early Phase 1 Pulmonary Hypertension Trial, Recruiting NCT07662655 Sponsor: Xiamen Cardiovascular Hospital, Xiamen University Condition: Pulmonary Hypertension
Back to Pulmonary Hypertension

Early Phase 1 Pulmonary Hypertension Trial, Recruiting

NCT07662655
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 80 years old
  • You have been diagnosed with high blood pressure in the lungs (pulmonary hypertension, confirmed by a specific heart test called right heart catheterization) at least 3 months after having a successful heart valve repair procedure called M-TEER, and you have been on recommended medications for this condition for at least 2 months
  • Your anatomy and heart condition do not prevent you from having a procedure called PADN (a treatment targeting nerves in the pulmonary artery — confirm with trial site if unsure whether this applies to you)
  • You are willing to read, understand, and sign a consent form allowing your health information to be used for the study
  • You are willing to follow all required treatment visits and follow-up appointments throughout the study

Who may not be able to join:

  • Your heart is not pumping enough blood to meet your body's needs (low cardiac output — confirm with trial site)
  • Your kidneys are not working well enough (kidney function below a certain level, measured by a blood test)
  • Your heart's pumping strength is significantly reduced (below 30% on an ultrasound of the heart)
  • You have a serious blood disorder, a very low platelet count, serious or widespread bleeding, or bleeding in the brain
  • You have a whole-body inflammatory disease, cancer, narrowing of certain heart valves, or another heart condition that requires surgery or a procedure
  • You currently have an active infection affecting your whole body
  • Your overall health is poor due to serious illness affecting multiple body systems
  • You have a specific lung condition called pulmonary veno-occlusive disease
  • You are in a state of severe physical deterioration (cachexia — extreme unintended weight and muscle loss)
  • Your pulmonary hypertension has been classified as WHO Group 1, 3, 4, or 5 (specific medical categories — confirm with trial site)
  • You are expected to need another surgery or medical procedure within the next 6 months
  • Your life expectancy is less than 12 months
  • You have a known allergy to any medications or metal materials used in this study
  • You are currently breastfeeding, pregnant, or planning to become pregnant within the next year
  • You have taken part in another drug or medical device clinical trial in the past 3 months
  • The trial doctor decides there is any other reason that makes participation unsuitable for you

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Phone: +8618033997788

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
Xiamen Cardiovascular Hospital, Xiamen University
Registry
ClinicalTrials.gov
Start date
6 June 2026
Est. completion
31 May 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Clinical worsening event

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov